174847-52-0

Upstream product

• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 885958-71-4 (3RS,4RS)-1-benzyl-4-methyl-pyrrolidine-3-carboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 74880-20-9 3(S)-amino-l-benzyl-4(S)-methylpyrrolidine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1334481-84-3 3(S)-[(t-butoxycarbonyl)amino]-4(R)-methyl-pyrrolidine 
• 174727-06-1 1-benzyl-3-(N-methyl-tert-butyloxycarbonylamino)-4-methylpyrrolidine 
• 1334481-84-3 trans-3-tert-butoxycarbonylamino-4-methylpyrrolidine 
• 127199-55-7 tert-butyl N-((3R,4R)-4-methylpyrrolidin-3-yl)carbamate 

Relevant academic research and scientific papers

BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS

The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and/or diabetes.

1-cyclopropyl-6-fluoro-8-alkyl-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid derivatives

Novel 4-oxoquinoline-3-carboxylic acid compounds of the formula: STR1 wherein R2 is 1-pyrrolidinyl which may have 1 to 2 substituents selected from the group consisting of (i) C1 -C6 alkyl, (ii) amino-(C1 -Csub

Pyridonecarboxylic acid derivatives and antibacterial pharmaceutical compositions thereof

Pyridonecarboxylic acid derivatives of the following formula, STR1 wherein R is hydrogen atom or lower alkyl group, R1 is lower alkyl group, cycloalkyl group or haloalkyl group, Y is hydrogen atom or halogen atom, or Y and R1 are STR